MedDataX Logo

Micardis®. Observational Study in Patients With Essential Hypertension

NCT ID: NCT02200094

Last Updated: 2014-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4532 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

NCT02238262

Hypertension
COMPLETED

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

NCT02176850

Hypertension
COMPLETED

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

NCT02242331

Hypertension
COMPLETED

Pharmacovigilance and Patient Compliance in Hypertensive Patients

NCT02200575

Hypertension
COMPLETED

Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring

NCT02242318

Hypertension
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Outpatients with essential hypertension

Low dose of Telmisartan, once daily

Intervention Type DRUG

High dose of Telmisartan, once daily

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low dose of Telmisartan, once daily

Intervention Type DRUG

High dose of Telmisartan, once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Micardis® Micardis®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of either sex over the age of 18 years suffering from essential hypertension requiring treatment according to the physician

Exclusion Criteria

* Hypersensitivity to the active component or to any of the excipients
* Pregnancy and lactation
* Biliary obstructive disorders
* Severe hepatic impairment
* Severe renal impairment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.361

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
NCT02177396 COMPLETED PHASE3
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
NCT00240448 COMPLETED PHASE4
Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
NCT02242851 COMPLETED
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
NCT00638911 COMPLETED
Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose
NCT00034840 COMPLETED PHASE4
Telmisartan in Mild to Moderate Hypertensive Patients
NCT02260089 COMPLETED PHASE4
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
NCT02248129 COMPLETED
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
NCT00168779 COMPLETED PHASE4
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
NCT00219154 COMPLETED PHASE3
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
NCT05843162 UNKNOWN PHASE4
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
NCT00909038 COMPLETED
Telmisartan Tab Hypertension
NCT00890084 COMPLETED
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
NCT02521246 WITHDRAWN PHASE3
The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
NCT00471003 COMPLETED
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
NCT00500604 COMPLETED PHASE4
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
NCT02261116 COMPLETED PHASE4
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
NCT00294710 COMPLETED PHASE3
Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)
NCT00400218 COMPLETED PHASE3
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
NCT04218552 COMPLETED PHASE2
Antihypertensive Medications and the Risk of Sepsis
NCT02248896 COMPLETED
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
NCT00902304 COMPLETED PHASE4
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 COMPLETED PHASE3
Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
NCT02016183 COMPLETED
Antihypertensive Efficacy of Fixed Combination Drug
NCT01211314 TERMINATED PHASE4
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
NCT00696436 COMPLETED PHASE3